- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
ALK Inhibitors in Nonsmall Cell Lung Cancer ; volume:42 ; number:01 ; year:2021 ; pages:067-070
Indian journal of medical & paediatric oncology ; 42, Heft 01 (2021), 067-070
- Contributor
-
Garg, Nitish
Kothari, Rushabh
- DOI
-
10.1055/s-0041-1729728
- URN
-
urn:nbn:de:101:1-2021081213511943038716
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Garg, Nitish
- Kothari, Rushabh
Other Objects (12)
Second- and third-generation ALK inhibitors for non-small cell lung cancer
The combined effect of ALK inhibitors and radiotherapy in non-small cell lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer
Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
Second- and third-generation ALK inhibitors for non-small cell lung cancer
The combined effect of ALK inhibitors and radiotherapy in non-small cell lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer
Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer
Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer
Second- and third-generation ALK inhibitors for non-small cell lung cancer
The combined effect of ALK inhibitors and radiotherapy in non-small cell lung cancer
Gingival Metastasis of ALK Rearranged Non-Small Cell Lung Cancer
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer
Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer
Primary Resistance to ALK Inhibitors in a Patient with Nonsmall Cell Lung Cancer with ALK Rearrangement: A Case Report with Review of Literature
Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients
Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer